Clinical trials: Allogeneic Disease
Tooth Loss
Allogenic Bone Block for Oro-Antral Communication Closure for Subsequent Implant Placement
13 patients will be included in this study with a badly destructed upper molar indicated for extraction. Cone beam computerized tomography images revealed the presence of a large bone defect associated with oro-antral…
- Trial name
- CAD-CAM (NCT07604142)
- Testing
- Extraction will be performed atraumatically using a piezotome surgical motor with an extraction kit
- Where
- Egypt
- Volunteers
- 13 people
- Sponsor
- Tanta University
Cancer
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
RATIONALE: White blood cells that have been treated in the laboratory may kill cells that are infected with cytomegalovirus. PURPOSE: This phase I trial is studying how well cytotoxic T cells work in treating patients who have…
- Trial name
- NCT00769613
- Testing
- cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Milton S. Hershey Medical Center
Leukemia
Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)
Primary Objective: To determine the safety and maximum tolerated dose of CMA-676 as part of an intensive but nonmyeloablative preparative regimen in older or medically infirm patients undergoing mini-allogeneic peripheral blood…
- Trial name
- NCT00038805
- Testing
- Mylotarg
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Malignancies
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
The researchers are doing this study to compare 2 different GVHD prevention (prophylaxis) approaches. The researchers will see which approach is good or more effective at preventing chronic GVHD until 1 year after allogeneic…
- Trial name
- NCT07359859
- Testing
- Cyclophosphamide, Mycophenolate Mofetil, Ruxolitinib
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation
G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) appears to be an efficient tool to cure refractory anemia with excess blasts-1 (RAEB-1), refractory anemia with excess blasts-2 (RAEB-2) and acute myeloid leukemia…
- Conditions
- Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning
- Trial name
- NCT02744742
- Testing
- Decitabine, Busulfan (BU), Cyclophosphamide (CY)
- Where
- China
- Volunteers
- 202 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hematological Malignancies
Nonmyeloablative Stem Cell Transplant in Elderly
The study aimed to evaluate the efficacy of a nonmyeloablative conditioning consisting of fludarabine and total body irradiation in patients older than 60 years of age
- Trial name
- NCT00382759
- Testing
- stem cell transplant
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Azienda Ospedaliera San Giovanni Battista
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome
This phase I trial tests the safety, side effects, best dose and how well arsenic trioxide works to prevent relapse in patients undergoing allogenic stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic…
- Trial name
- NCT07737769
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Arsenic Trioxide, Biospecimen Collection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Michigan Rogel Cancer Center
Sickle Cell Disease
Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)
The investigators propose to determine the engraftment and transplant related morbidity and mortality after a non-myeloablative allogeneic hematopoietic stem cell transplant protocol using immune- suppressive agents and low-dose…
- Trial name
- NCT01499888
- Testing
- Allogeneic Non-Myeloablative Stem Cell Transplantation, Alemtuzumab, Sirolimus
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Illinois Chicago
Mycosis Fungoides, Sezary Syndrome
Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
This study will investigate the safety and effectiveness of a modified donor stem cell transplantation procedure for treating advanced mycosis fungoides (MF), a lymphoma primarily affecting the skin, and Sezary syndrome (SS), a…
- Trial name
- NCT00047060
- Testing
- A matched peripheral donor stem cells, cyclosporine, fludarabine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Transplant-Related Disorder
A Cohort Study on the Association Between the ANS Function and Acute GvHD
This is a prospective observational study. The investigators plan to utilize this model as a tool for early classification and interrogate ANS function of transplant recipients.
- Trial name
- NCT07374874
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Allogeneic Hematopoietic Cell Transplant Recipients
Prospective Phase II Study for Assessment of Regulatory Immune Cell Populations After Allogeneic HSCT
Allogeneic hematopoietic cell transplantation offers high cure rates for patients with hematological and oncological diseases. Graft-versus-host disease (attack of donor's white blood cells on patient's tissues) is a serious…
- Trial name
- NCT00587574
- Where
- 2 sites in Austria, Czechia
- Volunteers
- 150 people
- Sponsor
- Medical University of Vienna
Metastatic Pancreatic Cancer
MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial)
Pancreatic cancer is expected to be the second leading cause of cancer-related death in 2020. Pancreatic cancer is known as an immunological cold tumor.
- Trial name
- REACtiVe-2 (NCT05650918)
- Testing
- MesoPher, Mitazalimab
- Where
- Netherlands
- Volunteers
- 22 people
- Sponsor
- Joachim Aerts, MD PhD
CMV Infection, Persistent CMV Viremia
Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is to see how well transfusions of T-cells work in treating CMV. Tcells are a type of white blood cell that helps protect the body from infection.
- Trial name
- NCT02136797
- Testing
- CMVpp65 Specific T-cells
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
COVID-19 Infection
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19
This study is to explore the safety and efficacy of using UCMSC01 in patients with COVID-19 infection via IV stem cell administration.
- Trial name
- UMSC01 (NCT05501418)
- Testing
- Allogeneic umbilical cord mesenchymal stem cells, Controlled normal saline
- Where
- Taiwan
- Volunteers
- 75 people
- Sponsor
- Ever Supreme Bio Technology Co., Ltd.
Sickle Cell Disease
Stem Cell Transplantation With Identical Donors for Patients With Sickle Cell Disease
This protocol studied the effect of administration of a myeloablative pretransplant preparative regimen followed by an infusion of donor stem cells in children with severe sickle cell disease.
- Trial name
- NCT00186810
- Testing
- Busulfan, Cyclophosphamide, Horse ATG, Allogeneic stem cell transplant
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- St. Jude Children's Research Hospital
Stroke
Cord Blood Infusion for Ischemic Stroke
This is a phase one study investigating the safety of a single, intravenous infusion of banked allogeneic umbilical cord blood in subjects following an acute ischemic stroke.
- Trial name
- NCT02397018
- Testing
- allogeneic umbilical cord blood
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Joanne Kurtzberg, MD
Lymphoma
Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloablative ASCT
Evaluate the safety of natural killer (NK) cell infusion using CD56 monoclonal antibody selected with Miltenyi Biotec system following nonmyeloablative stem cell transplantation (SCT) from matched donors.
- Trial name
- NCT00586690
- Testing
- NK Cell infusion using CD56 monoclonal antibody, Donor Apheresis
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- David Rizzieri, MD
Hematologic Diseases, Stem Cell Transplant Complications
Prospective Survey of CMV, Herpesviruses Infections and Diseases in Allo-HSCT
Prospective observational study of epidemiological surveillance, multicenter, non-profit, spontaneous, Italian with objective to describe the incidence of CMV infections and diseases in adult and pediatric patients undergoing…
- Conditions
- Hematologic Diseases, Stem Cell Transplant Complications, Cytomegalovirus Viremia, Herpesvirus Infection
- Trial name
- CYTOALLOSURVEY (NCT04412811)
- Where
- 50 sites in Italy
- Volunteers
- 1,310 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, L1
Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation
This is a Phase 1, open-label, single center study of short-course oral venetoclax therapy prior to non-myeloablative conditioning with fludarabine and cyclophosphamide in subjects with haematological malignancies who are planned…
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, L1, Leukemia, Lymphoblastic, Acute, L2, Myelodysplastic Syndromes
- Trial name
- VICTORY (NCT05005299)
- Testing
- Venetoclax, Fludarabine, Cyclophosphamide
- Where
- Australia
- Volunteers
- 18 people
- Sponsor
- Melbourne Health
Severe Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria
Unrelated Donor Stem Cell Transplantation
The purpose of this study is to provide an opportunity for patients with malignancies or bone marrow failure states who lack a suitable sibling donor to undergo allogeneic hematopoietic progenitor cell transplantation using cells…
- Conditions
- Severe Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT01364363
- Testing
- Allogeneic transplantation
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Scripps Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.